GO
Loading...

Celgene Corp

More

  • Final Glance: Biotechnology companies Thursday, 24 Jul 2014 | 6:22 PM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $122.26. Biogen Idec fell$. 81 or. 2 percent, to $336.79. Celgene Corp. fell $2.93 or 3.3 percent, to $86.19.

  • Midday Glance: Biotechnology companies Thursday, 24 Jul 2014 | 1:23 PM ET

    Biogen Idec fell$. 94 or. 3 percent, to $336.66. Celgene Corp. fell $3.22 or 3.6 percent, to $85.90. Gilead Sciences Inc. rose$. 04 or percent, to $90.38.

  • July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

  • Early Glance: Biotechnology companies Thursday, 24 Jul 2014 | 11:37 AM ET

    Amgen Inc. fell$. 51 or. 4 percent, to $121.50. Biogen Idec rose$. 29 or. 1 percent, to $337.89. Celgene Corp. fell $3.63 or 4.1 percent, to $85.49.

  • July 24- Celgene Corp posted a 25 percent rise in quarterly profit, beating the average analyst estimate by a cent, helped by robust sales of its flagship cancer drug, Revlimid. The U.S. biotechnology company also raised its 2014 adjusted earnings outlook to $3.60- $3.65 per share, from $3.50- $3.60, and revenue forecast to $7.60 billion from $7.50 billion.

  • Final Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Amgen Inc. rose $2.08 or 1.7 percent, to $121.11. Biogen Idec rose $1.17 or. 4 percent, to $303.67. Celgene Corp. rose $1.35 or 1.6 percent, to $86.66.

  • Midday Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Amgen Inc. rose $1.68 or 1.4 percent, to $120.71. Biogen Idec rose $2.64 or. 9 percent, to $305.14. Celgene Corp. rose $1.30 or 1.5 percent, to $86.61.

  • Early Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 11:16 AM ET

    Amgen Inc. rose $1.30 or 1.1 percent, to $120.33. Biogen Idec rose $5.25 or 1.7 percent, to $307.75. Celgene Corp. rose $1.69 or 2.0 percent, to $87.00.

  • Midday Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Amgen Inc. rose$. 05 or percent, to $116.91. Biogen Idec fell $6.64 or 2.1 percent, to $305.36. Celgene Corp. fell$. 70 or. 8 percent, to $86.08.

  • Early Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Amgen Inc. rose$. 29 or. 3 percent, to $117.16. Biogen Idec fell $4.28 or 1.4 percent, to $307.72. Celgene Corp. rose$. 21 or. 2 percent, to $86.99.

  • Midday Glance: Biotechnology companies Monday, 14 Jul 2014 | 1:29 PM ET

    Amgen Inc. fell$. 54 or. 5 percent, to $119.23. Biogen Idec fell $2.91 or. 9 percent, to $319.31. Celgene Corp. fell $1.01 or 1.1 percent, to $88.18.

  • Early Glance: Biotechnology companies Monday, 14 Jul 2014 | 10:47 AM ET

    Amgen Inc. fell$. 27 or. 2 percent, to $119.50. Biogen Idec fell$. 76 or. 2 percent, to $321.46. Celgene Corp. fell$. 93 or 1.0 percent, to $88.26.

  • July 9- Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket. Celgene said it would continue the study unchanged based on a recommendation by an independent data monitoring committee.

  • July 9- Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.

  • FDA approves Spectrum Pharma's blood cancer drug Thursday, 3 Jul 2014 | 11:19 AM ET

    July 3- Spectrum Pharmaceuticals Inc's drug for the treatment of an aggressive form of blood cancer was granted an accelerated approval by the U.S. Food and Drug Administration on Thursday. Beleodaq is the third drug to win approval for the condition since 2009, the other two being Spectrum's injection Folotyn and Celgene Corp's drug Istodax.

  • How to play stocks in the second half of 2014 Tuesday, 1 Jul 2014 | 10:32 AM ET
    Traders work the floor of the New York Stock Exchange.

    While stocks have generally moved higher, winning themes have emerged for the second half of the year.

  • Look for more upside in these biotech names: Pro Tuesday, 24 Jun 2014 | 2:48 PM ET

    Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.

  • Midday movers: Coach, Kroger, Markit & More Thursday, 19 Jun 2014 | 12:38 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of Thursday's midday movers:

  • Beleaguered biotechs about to rally: Charts Wednesday, 4 Jun 2014 | 6:26 PM ET

    For the past several months biotech stocks have fallen out of favor on Wall Street. That may be about to change.

  • Midday movers: Apple, Astrotech, Blackberry & More Thursday, 29 May 2014 | 12:20 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of Thursday's midday movers: